AI in Drug Discovery Startup Funding 2025-2026

What are all the funding deals in the AI in drug discovery market from August 2025 to September 2026?

The table below lists every qualifying disclosed equity financing identified for pure-play AI in drug discovery companies between August 2025 and September 2, 2026. We define the AI in drug discovery market as AI-enabled software and related services that materially support target identification, hit and lead generation, lead optimization, de novo design, drug repurposing, or preclinical prediction and candidate assessment before human trials.

Each row shows the company, what it does, its category, the announcement month, funding stage, disclosed round size, region, and main investors. For a wider view of the companies, categories, funding patterns, and competitive landscape, see our AI Drug Discovery market report.

How active has fundraising been in the AI in drug discovery market?

As of September 2026, fundraising in the AI in drug discovery market has been active across the past 12 months, with 29 qualifying financing announcements and at least $3.797B of disclosed capital in the full August 2025 to September 2, 2026 dataset. The 29 deals came from 28 unique companies because Chai Discovery raised twice during the period.

Deal formation is much steadier than capital deployment. Across the 14 calendar months touched by the research window, the dataset averages 2.07 deals per month and has a median of 2 deals per month.

Dollar flow is much more volatile. Average capital raised per calendar month is at least $271.23M, while median monthly capital is $75M, which shows how strongly a small number of financing events pull the average upward.

Rounds of $50M or less account for approximately $378.15M. That means the underlying flow of ordinary venture financings is meaningful, but it is much smaller than the $3.797B headline total suggests.

For more detail on the companies driving this financing activity, see our full AI Drug Discovery market report.

How concentrated has fundraising been in the AI in drug discovery market?

As of September 2026, fundraising in the AI in drug discovery market has been extremely concentrated over the past 12 months. Isomorphic Labs' $2.1B financing alone represents approximately 55.3% of all disclosed capital in the dataset.

The top 3 deals reach approximately 79.45% of capital. Those financings are Isomorphic Labs at $2.1B, Earendil Labs at $787M and Chai Discovery's $130M Series B.

The top 5 deals account for approximately 84.72% of total capital, while the top 10 reach roughly 92.6%. Most of the market's dollar value therefore comes from a very short list of unusually large financings.

This concentration changes how the headline total should be interpreted. A rise or fall in annual AI drug discovery funding can reflect only one or two platform financings rather than a broad change in financing conditions across the market.

How much of the AI in drug discovery funding signal is driven by outliers?

As of September 2026, the funding signal in the AI in drug discovery market is heavily driven by outliers over the past 12 months. The average disclosed round is at least $130.94M, while the median is only approximately $23M.

The roughly 5.7x gap between the average and median is primarily a concentration effect. Isomorphic Labs contributes $2.1B and Earendil Labs contributes another $787M, so ordinary startup financings are mathematically overwhelmed in the market-wide average.

Eight of the 29 deals are above $50M, representing 27.59% of deal count. By contrast, the remaining financings of $50M or less collectively contribute only about $378.15M.

Only three rounds are cleanly and strictly above $100M using conservative disclosed amounts: Chai Discovery at $130M, Earendil Labs at $787M and Isomorphic Labs at $2.1B. Iambic technically disclosed more than $100M, but its exact value is unknown and is represented at a $100M floor in the calculations.

Is the AI in drug discovery market broad with many fundable companies, or narrow with a few winners?

As of September 2026, the AI in drug discovery market has broad company formation but a narrow set of capital winners over the past 12 months. The dataset includes 28 unique companies across 29 deals, yet the top 3 financings capture nearly four-fifths of disclosed capital.

The breadth is clearest at the early stages. Seed and Series A together account for 20 of 29 deals, or approximately 69% of all financing announcements.

The narrowness appears when capital is measured rather than company count. Those same Seed and Series A rounds account for only approximately $447.05M, or 11.77% of all disclosed capital.

The result is a barbell-shaped market. Many companies can still form and raise institutional capital, but the largest pools of money are being concentrated into a small group of platforms investors believe can produce therapeutic assets at scale.

Is AI in drug discovery mostly an early-stage formation market or a late-stage scaling market?

As of September 2026, the AI in drug discovery market combines strong early-stage formation with highly concentrated late-stage scaling over the past 12 months. Seed and Series A generate most of the deals, while Series B and Growth Equity absorb most of the capital.

Seed plus Series A represents approximately $447.05M, or 11.77% of disclosed funding. Series B plus Growth Equity represents at least $2.518B, or 66.31%.

Unknown-stage financings add another $832M, or 21.91% of capital, largely because Earendil Labs' $787M announcement does not carry a conventional single-round label. Treating all of that Unknown bucket as late stage would make the stage analysis look more precise than the evidence allows.

The Series B median is $100M, compared with approximately $22.5M for Series A and $10.25M for Seed. That progression shows a real scaling ladder even though the overall market statistics are distorted by billion-dollar rounds.

For a deeper view of funding stages and company maturity, see our AI Drug Discovery funding analysis.

Which categories attract the most investor attention in the AI in drug discovery market?

As of September 2026, De Novo Design attracts the most investor attention in the AI in drug discovery market over the past 12 months. It accounts for 11 of 29 deals and approximately $3.485B of disclosed capital.

That equals 37.93% of financing announcements but 91.77% of all capital. The category includes Chai Discovery, Isomorphic Labs, Iambic Therapeutics, Earendil Labs, Aureka Biotechnologies and several other model-to-molecule platforms.

AI Lead Optimization and AI Lead Generation each account for 6 deals, or 20.69% of activity. Their dollar totals are much smaller at approximately $154.4M and $111.3M respectively.

AI Target Discovery contributes 3 deals and $34M, while Preclinical Prediction AI contributes 3 deals and approximately $12.95M. No qualifying discrete financing remained in the standalone AI Drug Repurposing category after the dataset filters were applied.

We break down these category differences further in our report on the AI Drug Discovery market.

Which categories attract disproportionately large checks in the AI in drug discovery market?

As of September 2026, De Novo Design is the only category attracting clearly disproportionate checks in the AI in drug discovery market over the past 12 months. Its capital-share-to-deal-share ratio is approximately 2.42x.

The average De Novo Design deal is approximately $316.77M and the median is approximately $80M. That is dramatically higher than AI Lead Optimization, where the average is approximately $25.73M and the median about $19M.

AI Lead Generation has a capital-share-to-deal-share ratio of only 0.14x, while AI Target Discovery is approximately 0.09x and Preclinical Prediction AI approximately 0.03x. Those categories generate meaningful company activity without attracting comparable dollar intensity.

The difference is partly structural. Companies that own therapeutic assets and operate experimental loops need more capital for laboratories and preclinical programs, while discovery software and candidate-assessment platforms can often reach pharmaceutical customers with much smaller balance sheets.

Which geographies matter most for fundraising in the AI in drug discovery market?

As of September 2026, Europe and North America matter most for fundraising in the AI in drug discovery market over the past 12 months. Together they account for approximately 95.95% of disclosed capital and 23 of 29 financing announcements.

Europe leads on headline dollars with approximately $2.177B, or 57.33% of total capital, from 9 deals. Its average round is approximately $241.86M, but its median is only about $10M.

North America leads on deal count with 14 financings, or 48.28% of activity, representing at least $1.466B. The region's median financing is approximately $48.5M, materially above Europe's median.

Asia-Pacific contributes 5 deals and approximately $138.1M, while the Middle East contributes one $16M deal. Latin America and Africa contribute no qualifying financing announcements in the disclosed sample.

For more context on the geographic competitive landscape, explore our AI Drug Discovery market deck.

Is the AI in drug discovery opportunity set broad geographically or concentrated in a few hubs?

As of September 2026, the AI in drug discovery opportunity set is geographically concentrated over the past 12 months. North America and Europe together capture almost 96% of disclosed capital and nearly four-fifths of deal count.

The concentration differs depending on the metric. Europe appears dominant on dollars because Isomorphic Labs alone raised $2.1B, while North America produces substantially more financing events and has a much higher median round.

Asia-Pacific is technically active but much lighter on capital. Its 5 deals represent 17.24% of financing announcements but only approximately 3.64% of disclosed dollars.

The Middle East represents only one qualifying deal, Scala Biodesign's $16M Series A. No qualifying disclosed financings were identified in Latin America or Africa during the research window.

Is AI in drug discovery a market of small experiments or scaled financings?

As of September 2026, the AI in drug discovery market contains both small experiments and scaled financings over the past 12 months, but the dollar distribution is dominated by the scaled end. The median disclosed round is approximately $23M, while the average is at least $130.94M.

Four deals are below $5M, 9 fall between $5M and below $20M, and 8 sit between $20M and $50M inclusive. That means 21 of 29 financings are $50M or less.

At the other end, 8 deals are above $50M. Those few larger financings explain why the market's total capital is so much more concentrated than its deal count.

The $378.15M raised in financings of $50M or less is therefore a useful underlying-market benchmark. It better represents normal startup financing capacity than the $3.797B headline total, which is heavily shaped by Isomorphic Labs and Earendil Labs.

For a fuller view of financing benchmarks and the companies behind them, see our AI Drug Discovery market report.

Is financing in the AI in drug discovery market mainly first-time funding or follow-on capital?

As of September 2026, financing in the AI in drug discovery market is mainly follow-on capital over the past 12 months. Based on the financing classifications in the dataset, 21 of 29 qualifying announcements are follow-ons and 8 are first publicly identified institutional or launch financings.

That means approximately 72% of disclosed deals are follow-ons. Investors are still backing new company formation, but most visible financing activity goes to businesses that have already raised or been capitalized before.

The pattern becomes stronger at the top of the market. Isomorphic Labs, Earendil Labs, Chai Discovery, Iambic Therapeutics, Aureka Biotechnologies and MindRank are all follow-on financings rather than first institutional checks.

This makes repeat fundraising an important credibility signal in AI drug discovery. A company's ability to re-raise after technical progress, experimental validation or pharma deployment carries more information than a first financing announcement by itself.

Who are the investors that appear the most in AI in drug discovery fundraising?

As of September 2026, a small group of investors appears repeatedly across AI in drug discovery fundraising over the past 12 months. The strongest repeat activity clusters around companies building frontier molecular models, therapeutic-design platforms and proprietary experimental loops.

Dimension or Dimension Capital appears in at least Tamarind Bio and Earendil Labs, plus Chai Discovery financings depending on fund-name normalization. Thrive Capital appears in Chai Discovery's Series A and Series B and in Isomorphic Labs.

Yosemite appears in both Chai Discovery rounds and Proxima, while Alexandria Venture Investments appears in Iambic Therapeutics, Proxima and Fathom Therapeutics. Neo also appears repeatedly around Chai Discovery and Topos Bio.

OpenAI and Menlo Ventures each appear in both Chai Discovery financings. TLV Partners appears in Converge Bio and Scala Biodesign, Granite Asia in ChemLex and Aureka Biotechnologies, redalpine in DaltonTx and Helical, and Seedcamp in DaltonTx and Sable Bio.

Y Combinator also appears in Tamarind Bio and 10x Science. These counts should be read as disclosed syndicate appearances rather than measures of dollars personally invested, because financing announcements generally disclose total round size without individual investor check sizes.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.